Condition
Blau Syndrome
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 4 (1)
Trial Status
Enrolling By Invitation2
Recruiting2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00001244Recruiting
Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)
NCT06688838Enrolling By InvitationPrimary
Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome
NCT01793168Recruiting
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT06206811Phase 1Completed
Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants
NCT06660329Phase 4Enrolling By InvitationPrimary
Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome
Showing all 5 trials